KEY POINTS
- This prospective substudy of the Danish Anal Cancer Group-I cohort (DACG-I; NCT05570279) evaluated sexual function in men receiving curative-intent radiotherapy for anal squamous cell carcinoma between 2015 and 2020 at two Danish centers. 80 men were enrolled, 76 were available at baseline, and assessments were scheduled at one, three, and five years using EORTC QLQ-C30/CR29 questionnaires and CTCAE v4.0; the median baseline age was 61.8 years.
- Patients received 54–64 Gy in 30–32 fractions using IMRT or VMAT, with 48–51.2 Gy to elective nodal regions. 53/76 patients (69.7%) received concurrent chemotherapy, while daily CBCT was used for image guidance. Genital structures were inconsistently defined as either the penile bulb or entire penis, and no standardized sexual-function dose constraint or dose-response analysis was available.
- Clinician-assessed grade ≥2 erectile dysfunction increased from 11.9% at baseline to 39.3% at three years. At baseline, 73.1% had no clinician-recorded erectile dysfunction, compared with fewer than 38% at three years. Some improvement was observed at five years, but clinically relevant dysfunction remained common.
- Patient-reported erectile function deteriorated more substantially than clinician grading suggested. Mean EORTC erectile-difficulty scores increased by 18.4 points at one year (95% CI 10.1–26.7) and 23.5 points at three years (95% CI 15.3–31.8) relative to baseline, representing moderate and major clinically important deterioration, respectively. The proportion reporting severe difficulties increased from 15.4% before RT to 34% at three years, remaining 23.3% at five years.
- Sexual interest remained comparatively stable despite worsening erectile function. Mean sexual-interest score was 41.9 at baseline, with changes of +0.9 points at three years and −2.2 points at five years, neither statistically significant. This divergence suggests that preserved sexual desire should not be interpreted as preserved sexual function or absence of treatment-related distress.
- Ejaculatory dysfunction also increased, with clinician-graded grade ≥2 symptoms rising from approximately 4.5% at baseline to 12.3% at three years. Agreement between patient-reported erectile difficulties and clinician-assessed toxicity was only moderate, with weighted κ values of 0.49 at baseline, 0.51 at three years, and 0.54 at five years. Patients generally reported more frequent or severe problems than clinicians documented.
- Long-term interpretation is constrained by attrition: 71 patients remained in follow-up at one year, 64 at three years, and 39 at five years, with some patients not originally scheduled for five-year assessment. Participants lost to follow-up tended to have poorer performance status, while baseline sexual dysfunction, comorbidities, aging, and systemic treatment could also influence outcomes. No penile bulb, neurovascular, or hormonal dose-response relationship was evaluated.
CLINICAL TAKEAWAY
Erectile and ejaculatory dysfunction should be recognized as important long-term survivorship concerns after curative radiotherapy for anal squamous cell carcinoma, even when sexual interest remains preserved. These prospective findings support routine patient-reported sexual-function assessment and proactive supportive care, but do not identify which radiation dose parameters or preventive interventions reduce the risk.